QPPV.COM KNOWLEDGE ASSESSMENT

Professional Knowledge Assessment: Alirocumab Classification, Mechanism, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Alirocumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which alternative explanation is particularly relevant when assessing an apparent inadequate LDL-C response during alirocumab treatment?

Non-adherence or changes in statin or other lipid-lowering therapy The fact that the medicine is administered subcutaneously, without further investigation The patient's product batch number alone The absence of an injection-site reaction

Question 2 of 10 Which follow-up package is most appropriate when evaluating an apparent inadequate lipid response to alirocumab?

Injection-site photographs only Baseline and serial LDL-C, adherence, concomitant lipid-lowering treatment, dosing and administration timing The patient's infection history alone Batch number without any clinical or laboratory information

Question 3 of 10 When exposure denominators are uncertain during aggregate review, what is the most scientifically appropriate practice?

Present a precise incidence rate based on an assumed denominator Hide the uncertainty because it may weaken the signal State the denominator limitation and interpret the observed pattern accordingly Exclude all reports from the analysis

Question 4 of 10 Which mechanistic sequence best explains alirocumab's intended LDL-lowering effect?

It binds circulating PCSK9, reduces PCSK9-mediated degradation of hepatic LDL receptors, increases receptor availability and lowers circulating LDL cholesterol It inhibits intestinal cholesterol absorption, increases biliary cholesterol excretion and lowers circulating LDL cholesterol It activates hepatic PCSK9, accelerates LDL-receptor degradation and reduces hepatic lipid uptake It directly dissolves atherosclerotic plaques by suppressing vascular inflammation

Question 5 of 10 A report describes itching after an alirocumab injection. Which follow-up would most directly improve assessment of a possible hypersensitivity reaction?

Only the patient's LDL-C value six months before treatment Onset relative to injection, distribution and phenotype, associated symptoms, objective findings, treatment and outcome Only the patient's family history of hypercholesterolaemia The number of cardiovascular risk factors without details of the reaction

Question 6 of 10 Which information would most directly support investigation of a possible alirocumab device, storage or product-quality issue?

The patient's cardiovascular risk score alone Storage and preparation details, device information, batch, complaint data and related-case information Only the patient's LDL-C response The historical date of EU authorisation without exposure details

Question 7 of 10 Why are preferred-term counts alone an insufficient basis for evaluating a possible alirocumab signal?

Preferred terms cannot be used in biological-product pharmacovigilance Several terms may represent one syndrome, while one term may include different mechanisms and clinical contexts Preferred terms automatically establish causality Counts are useful only when exposure denominators are known with certainty

Question 8 of 10 A follow-up questionnaire is sent for an alirocumab case, but the returned clinical information is never incorporated into the medical assessment. What is the principal process weakness?

The questionnaire was too specific to the event The system measured follow-up activity rather than whether clinically important information changed the assessment The case should automatically be closed because follow-up was attempted Medical review is unnecessary once a questionnaire has been issued

Question 9 of 10 Which inspection evidence would best demonstrate that an alirocumab pharmacovigilance system is functioning effectively?

The existence of a written procedure, without reviewing processed cases A high number of follow-up requests, regardless of their clinical content Traceable links from source information through case narrative, medical assessment, signal review and documented benefit-risk decisions A product dictionary without evidence of case use

Question 10 of 10 Which aggregate-review approach is most likely to reveal a clinically important subgroup-specific safety pattern?

Pooling all reports into a single overall count Reviewing only preferred-term frequencies without case narratives Stratifying by relevant factors such as indication, treatment phase, combination regimen, age and comorbidity Excluding reports with uncertain denominators

Professional Knowledge Assessment: Alirocumab Classification, Mechanism, Safety and Pharmacovigilance

Cookie Settings